Palo Alto, CA, United States of America

Robert L Wolfert

USPTO Granted Patents = 10 



Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 81(Granted Patents)


Location History:

  • San Diego, CA (US) (1996 - 2002)
  • Palo Alto, CA (US) (2007 - 2012)

Company Filing History:


Years Active: 1996-2012

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Innovations of Robert L. Wolfert in Cancer Risk Assessment

Introduction

Robert L. Wolfert is a notable inventor based in Palo Alto, California, recognized for his significant contributions to the field of cancer diagnostics. With a total of 10 patents to his name, he has focused on developing innovative methods and compositions that enhance the assessment of cancer risk, particularly prostate cancer.

Latest Patents

Wolfert's latest patents include the Pro108 antibody compositions and methods of use, which are pivotal in assessing cancer risk. This invention specifically relates to a method for evaluating the risk of prostate cancer by utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination. Furthermore, it extends to assessing the risk of ovarian, colon, breast, or stomach cancer through the use of Pro108 or specific antibodies targeting Pro108. The invention provides isolated anti-Pro108 antibodies that bind to Pro108 on mammalian cells in vivo. Additionally, it encompasses compositions that include an anti-Pro108 antibody and a carrier, which can be packaged in a kit. Other aspects of the invention involve isolated nucleic acids encoding anti-Pro108 antibodies and methods for producing these antibodies. The invention also outlines methods for killing Pro108-expressing cancer cells and treating cancers in mammals by administering therapeutically effective amounts of the anti-Pro108 antibody.

Career Highlights

Throughout his career, Robert L. Wolfert has worked with prominent companies such as Hybritech Incorporated and Diadexus, Inc. His work has significantly impacted the field of cancer diagnostics, leading to advancements that aid in the early detection and management of various cancers.

Collaborations

Wolfert has collaborated with esteemed colleagues, including Harry G. Rittenhouse and Stephen D. Mikolajczyk, contributing to the development of innovative cancer diagnostic methods.

Conclusion

Robert L. Wolfert's contributions to cancer risk assessment through his innovative patents and collaborations have made a lasting impact in the field of medical diagnostics. His work continues to pave the way for advancements in cancer detection and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…